0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Role of a Uterine-Placental Factor in the Cessation of the Semicircadian Rhythm of Tuberoinfundibular Dopaminergic Neuronal Activity at Midpregnancy in the Rat

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          During early pregnancy in the rat, the secretion of prolactin exhibits daily surges which appear to be related temporally to changes in the activity of tuberoinfundibular dopaminergic (TIDA) neurons. The present study was undertaken to determine:(1) the temporal relationships between the cessation of the prolactin surges at midpregnancy and the termination of the semicircadian pattern of TIDA neuronal activity, and (2) if the uterine-placental unit is required for the cessation of these patterns. TIDA neuronal activity was estimated from the rate of dopamine synthesis in the median eminence, which was measured in vivo by determining the rate of DOPA accumulation after the administration of an inhibitor of aromatic L-amino acid decarboxylase. Nocturnal surges of prolactin occurred on days 6–11 of pregnancy but not on days 12 and 13, while diurnal surges occurred on days 6–9. TIDA neurons exhibited a biphasic pattern of activity on days 8–10 of pregnancy with activity being significantly lower at 04.30 h than at 12.00 h. On days 11–13 of pregnancy, this pattern was lost and activity was constantly maintained at the higher values. Nocturnal surges of prolactin that normally cease after day 11 of pregnancy were still observed on days 12 and 13 if the pregnant rats were hysterectomized on day 6. Furthermore, the biphasic pattern of TIDA neuronal activity persisted until day 13 if pregnant rats were hysterectomized on day 6. The administration of bromocriptine, a dopaminergic agonist which in nonpregnant female rats reduces TIDA neuronal activity by virtue of its ability to reduce circulating concentrations of prolactin, reduced TIDA neuronal activity in 6-day pregnant animals, but was ineffective in 13-day pregnant rats. Bromocriptine was, however, able to reduce the activity of TIDA neurons on day 13 if the pregnant rats had been hysterectomized on day 6. These results suggest that at midpregnancy a uterine-placental factor takes over from prolactin in stimulating TIDA neurons; this factor appears to be responsible for terminating the semicircadian pattern of prolactin secretion.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1983
          1983
          26 March 2008
          : 36
          : 6
          : 409-414
          Affiliations
          Departments of Pharmacology/Toxicology and Physiology, Michigan State University, East Lansing, Mich., USA
          Article
          123491 Neuroendocrinology 1983;36:409–414
          10.1159/000123491
          6410298
          © 1983 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article